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pathway in 3T3-L1 cells 
Abstract 
The aim of this study was to investigate the mechanisms underlying the inhibitory effects of berberine 
(BBR) on olanzapine (OLZ)-induced adipogenesis in a well-replicated 3T3-L1 cell model. Oil-Red-O (ORO) 
staining showed that BBR significantly decreased OLZ-induced adipogenesis. Co-treatment with OLZ and 
BBR decreased the accumulation of triglyceride (TG) and total cholesterol (TC) by 55.58% ± 3.65% and 
49.84% ± 8.31%, respectively, in 3T3-L1 adipocytes accompanied by reduced expression of Sterol 
regulatory element binding proteins 1 (SREBP1), fatty acid synthase (FAS), peroxisome proliferator 
activated receptorγ (PPARγ), SREBP2, low-density lipoprotein receptor (LDLR), and hydroxymethylglutaryl-
coenzyme A reductase (HMGR) genes compared with OLZ alone. Consistently, the co-treatment 
downregulated protein levels of SREBP1, SREBP2, and LDLR by 57.71% ± 9.42%, 73.05% ± 11.82%, and 
59.46% ± 9.91%, respectively. In addition, co-treatment reversed the phosphorylation level of AMP-
activated protein kinase-α (AMPKα), which was reduced by OLZ, determined via the ratio of 
pAMPKα:AMPKα (94.1%) compared with OLZ alone. The results showed that BBR may prevent lipid 
metabolism disorders caused by OLZ by reversing the degree of SREBP pathway upregulated and the 
phosphorylation of AMPKα downregulated. Collectively, these results indicated that BBR could be used as 
a potential adjuvant to prevent dyslipidemia and obesity caused by the use of second-generation 
antipsychotic medication. 
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Abstract: The aim of this study was to investigate the mechanisms underlying the inhibitory effects
of berberine (BBR) on olanzapine (OLZ)-induced adipogenesis in a well-replicated 3T3-L1 cell model.
Oil-Red-O (ORO) staining showed that BBR significantly decreased OLZ-induced adipogenesis.
Co-treatment with OLZ and BBR decreased the accumulation of triglyceride (TG) and total cholesterol
(TC) by 55.58% ± 3.65% and 49.84% ± 8.31%, respectively, in 3T3-L1 adipocytes accompanied by
reduced expression of Sterol regulatory element binding proteins 1 (SREBP1), fatty acid synthase
(FAS), peroxisome proliferator activated receptor-γ (PPARγ), SREBP2, low-density lipoprotein
receptor (LDLR), and hydroxymethylglutaryl-coenzyme A reductase (HMGR) genes compared
with OLZ alone. Consistently, the co-treatment downregulated protein levels of SREBP1, SREBP2,
and LDLR by 57.71% ± 9.42%, 73.05% ± 11.82%, and 59.46% ± 9.91%, respectively. In addition,
co-treatment reversed the phosphorylation level of AMP-activated protein kinase-α (AMPKα),
which was reduced by OLZ, determined via the ratio of pAMPKα:AMPKα (94.1%) compared
with OLZ alone. The results showed that BBR may prevent lipid metabolism disorders caused
by OLZ by reversing the degree of SREBP pathway upregulated and the phosphorylation of AMPKα
downregulated. Collectively, these results indicated that BBR could be used as a potential adjuvant to
prevent dyslipidemia and obesity caused by the use of second-generation antipsychotic medication.
Keywords: berberine; olanzapine; adipogenesis; AMPKα; SREBPs; 3T3-L1 cells
1. Introduction
Second-generation antipsychotic drugs (SGAs), such as olanzapine (OLZ), have become first
line medication for treating schizophrenia symptoms and other mental disorders due to their lower
incidence of extra pyramidal symptoms (EPS) and improved tolerability compared with first-generation
antipsychotic drugs (FGAs) [1,2]. However, they cause troublesome metabolic side-effects such as
SGA-jnduced metabolic abnormalities, increased leptin [3], and decreased adiponectin levels [4],
weight gain, dyslipidemia, insulin resistance, and type II diabetes mellitus, which could further lead to
the risk of cardiovascular disease and premature death [5–8].
In past decades, accumulating evidence has indicated that OLZ could upregulate the
transcriptional level of sterol regulatory element binding protein (SREBP), which is a key factor
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for modulating lipid homeostasis in cultured cells (including glioma cells, liver cells, and adipocytes)
and rats [9–13]. The SREBP family has three isoforms—SREBP-1a, SREBP-1c and SREBP-2—that
are involved in lipogenesis and cholesterogenesis [14–17]. Furthermore, it has been demonstrated
that OLZ could augment SREBP-dependent lipid synthesis by suppressing AMP-activated protein
kinase α (AMPKα) activity in hepatocytes [10]. AMPKα is a major transcriptional regulator for
controlling hepatic energy metabolism [18–20]. It is plausible to suspect that AMPKα activation would
significantly ameliorate lipid metabolism dysregulation that occurs during OLZ treatment.
BBR, an isoquinoline derivative alkaloid extracted from Berberis and Coptis herbs such as
Hydrastis canadensis (goldenseal), Cortex phellodendri (Huangbai), and Rhizoma coptidis (Huanglian),
is a commonly used traditional Chinese medicine for treatment of microbial diarrhea [21,22]. In
addition, BBR has potential pharmacological effects, including effects on metabolic abnormalities, and
antiarrhythmic, antihypertensive, anticancer, antidiabetic, and antihyperlipidenmic effects [23–26].
Accumulated evidence has shown that BBR can reduce lipogenesis in vitro and in vivo through a series
of mechanisms, including the downregulation of the expression of peroxisome proliferator activated
receptor γ (PPARγ) [27]. Although BBR has been reported to inhibit clozapine and risperidone-induced
adipogenesis via SREBP-1 in 3T3-L1 cells [28], it is unclear whether SREBP-2 plays a role in the BBR
restraint of OLZ-induced adipogenesis. Likewise, BBR ameliorates lipid dysregulation in obesity
by managing the activity of peripheral and central AMPKα [29]. Additionally, it has been shown
that AMPK directly inhibits expression and/or activity of SREBP-1c [19,30]. Therefore, BBR has the
potential to prevent OLZ-induced dyslipidemia by acting on these relevant pathways.
In this study, we established an OLZ-induced adipogenesis model in 3T3-L1 adipocytes, which
was used to investigate multiple key genes that are involved in adipogesis (SREBP1, fatty acid
synthetase (FAS) and PPARγ) and cholesterogenesis (SREBP2, low-density lipoprotein receptor (LDLR)
and hydroxymethylglutaryl coenzyme A reductase (HMGR)). Furthermore, we examined whether
BBR modulates gene transcription and protein expression levels of the AMPKα–SREBP pathway and
its role in downregulating OLZ-induced adipogenesis in a 3T3-L1 cell model.
2. Results
2.1. Effects of Treatment with OLZ, BBR, or Both on 3T3-L1 Differentiation
To detect whether OLZ could increase the rate of adipogenesis, 3T3-L1 cells were exposed to
OLZ (0, 1, 10, and 50 µM) with DM for the first six days (Days 0–6), and were then stained with
Oil-Red-O (ORO) on Day 12. The effect of OLZ in facilitating differentiation of 3T3-L1 cells had a
dose-dependent response (Supplemental Experimental Section 1: Effects of Treatment with OLZ on
3T3-L1 Differentiation). 3T3-L1 adipocytes treated with 10 µM OLZ tended to be much larger and
prone to rupture, suggesting this concentration of OLZ could have the greatest effect on adipogenesis
(Figure S1). On this basis, 10 µM OLZ was used in the following investigation of BBR’s inhibitory
effects. Additionally, various concentrations of BBR (0, 0.675, 1.25, 2.5, and 5 µM) were added to the
3T3-L1 cells culture for six days (Supplemental Experimental Section 2: Effects of Treatment with
BBR on 3T3-L1 Differentiation). The inhibitory effect of BBR on adipogenesis of 3T3-L1 cells was a
dose-dependent response, and 5 µM BBR clearly reduced the number of lipid droplets stained with
ORO (Figure S2). Therefore, 5 µM BBR combined with 10 µM OLZ were added to the DM for six days
during the 3T3-L1 cell culture. Microscopic images of ORO staining showed that 5 µM BBR could
significantly reverse the enhancement of OLZ-induced oil droplet accumulation (Figure 1A–E).
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Figure 1. Olanzipine (OLZ) + Berberine (BBR) co-treatment reduced lipid droplet accumulation 
induced by OLZ in 3T3-L1 adipocytes. Representative images were randomly selected and sections 
of 3T3-L1 adipocytes stained with Oil-Red-O (ORO) treated with drugs. (A–E) ORO-stained cell 
morphology of lipid droplets in 3T3-L1 adipocytes treated with Vehicle (A); 1 μM Rosiglitazone 
(Ros) (B); OLZ alone (C); BBR alone (D); and OLZ + BBR co-treatment (E). Treated with DMSO as 
control. Treatment of 1 μM Ros used as positive control. Scale bars, 100 μm. 
2.2. Effects of Treatment with OLZ, BBR, or both on Biochemical Properties of 3T3-L1 Cells 
A 10 μM dose of OLZ-induced accumulation of triglycerides (TG) compared with controls  
(p < 0.05). A 5 μM BBR dose significantly decreased the degree of TG accumulation compared with 
the control (71.05% ± 9.2%, p < 0.01, Figure 2), which was consistent with the reduction in 
adipogenesis shown in cell imaging (Figure S2). Moreover, in order to study the candidate inhibitory 
effects of BBR on OLZ-induced adipogenesis, 5 μM BBR and 10 μM OLZ were exposed to 3T3-L1 
cells cultures. The results revealed that 3T3-L1 cells incubated in the presence of OLZ + BBR for six 
days decreased by 55.58% ± 3.65% compared with treatment with OLZ alone (p < 0.05) (Figure 2A).  
A potent PPARγ agonist and 1 μM Rosiglitazone (Ros) significantly increased adipogenesis and 
enhanced the degree of TG and total cholesterol (TC) accumulation approximately 2-fold and 
1.8-fold (p < 0.001), respectively. In addition, the TC assay suggested that treatment with OLZ alone 
could significantly enhance TC accumulation (59.5% ± 17.35%, p < 0.05). OLZ + BBR co-treatment 
markedly reduced the accumulation of TC induced by OLZ in 3T3-L1 cells (49.84% ± 8.31%, p < 0.05) 
(Figure 2B). However, treatment with BBR alone had no observable effect on TC accumulation. 
 
Figure 2. OLZ + BBR co-treatment could decrease the biochemical properties induced by OLZ in 
3T3-L1 adipocytes. The determination of triglyceride (TG) (A) and total cholesterol (TC) (B) 
accumulation in 3T3-L1 adipocytes treated with OLZ, BBR, or both on Day 12. Treatment with 
DMSO as the control. Treatment of 1 μM Ros used as positive control. Values given are the mean ± 
SEM (n = 3). (* p < 0.05, ** p < 0.01 and *** p < 0.001 vs. control, # p < 0.05 vs. treated with OLZ alone). 
Figure 1. Olanzipine (OLZ) + Berberine (BBR) co-treatment reduced lipid droplet accumulation induced
by OLZ in 3T3-L1 adipocytes. Representative images were randomly selected and sections of 3T3-L1
adipocytes stained with Oil-Red-O (ORO) treated with drugs. (A–E) ORO-stained cell morphology of
lipid droplets in 3T3-L1 adipocytes treated with Vehicle (A); 1 µM Rosiglitazone (Ros) (B); OLZ alone
(C); BBR alone (D); and OLZ + BBR co-treatment (E). Treated with DMSO as control. Treatment of 1 µM
Ros used as positive control. Scale bars, 100 µm.
2.2. Effects of Treatment with OLZ, BBR, or Both on Biochemical Properties of 3T3-L1 Cells
A 10 µM dose of OLZ-induced accumulation of triglycerides (TG) compared with controls
(p < 0.05). A 5 µM BBR dose significantly decreased the degree of TG accumulation compared with the
control (71.05% ± 9.2%, p < 0.01, Figure 2), which was consistent with the reduction in adipogenesis
shown in cell imaging (Figure S2). Moreover, in order to study the candidate inhibitory effects of
BBR on OLZ-induced adipogenesis, 5 µM BBR and 10 µM OLZ were exposed to 3T3-L1 cells cultures.
The results revealed that 3T3-L1 cells incubated in the presence of OLZ + BBR for six days decreased
by 55.58% ± 3.65% compared with treatment with OLZ alone (p < 0.05) (Figure 2A). A potent PPARγ
agonist and 1 µM Rosiglitazone (Ros) significantly increased adipogenesis and enhanced the degree of
TG and total cholesterol (TC) accumulation approximately 2-fold and 1.8-fold (p < 0.001), respectively.
In addition, the TC assay suggested that treatment with OLZ alone could significantly enhance TC
accumulation (59.5% ± 17.35%, p < 0.05). OLZ + BBR co-treatment markedly reduced the accumulation
of TC induced by OLZ in 3T3-L1 cells (49.84% ± 8.31%, p < 0.05) (Figure 2B). However, treatment with
BBR alone had no observable effect on TC accumulation.
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Figure 2. OLZ + BBR co-treatment could decrease the biochemical properties induced by OLZ in 3T3-L1
adipocytes. The determination of triglyceride (TG) (A) and total cholesterol (TC) (B) accumulation in
3T3-L1 adipocytes treated with OLZ, BBR, or both on Day 12. Treatment with DMSO as the control.
Treatment of 1 µM Ros used as positive control. Values given are the mean ± SEM (n = 3). (* p < 0.05,
** p < 0.01 and *** p < 0.001 vs. control, # p < 0.05 vs. treated with OLZ alone).
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2.3. Effects of Treatment with OLZ, BBR, or Both on the Expression of SREBP-Related Genes for Adipogenesis
in 3T3-L1 Cells
Figure 3A shows the effects of treatment with OLZ, BBR, or both on mRNA expression of the
SREBP pathway. Treatment with OLZ alone significantly augmented the mRNA expression of genes
involved in adipogenesis including Srebp1 and the downstream gene Fas compared with the control
group (92.4% ± 7.76%, 158.75% ± 22.73%, both p < 0.01). Treatment with BBR alone clearly decreased
the mRNA expression levels of Srebp1 and Fas compared with the control (55.45% ± 1.12%, p < 0.05,
80.79% ± 9.88%, p < 0.01, respectively). The OLZ + BBR co-treatment group markedly reversed
the upregulation of Srebp1 and Fas gene expression levels induced by OLZ alone (77.48% ± 7.66%,
81.37% ± 1.14%, both p < 0.001). Compared with the control, treatment with BBR alone clearly reduced
the gene expression level of Pparγ, which was a member of the adipogenesis related transcription
factors (70.51% ± 0.92%, p < 0.05). The OLZ + BBR co-treatment group distinctly lowered the mRNA
expression levels of Pparγ compared with OLZ alone (65.05% ± 9.04%, p < 0.01). However, treatment
with OLZ alone tended to have a higher expression of Pparγ gene expression levels than the control
group (p = 0.07) (Figure 3A). Treatment with OLZ alone also significantly increased the protein
expression level of SREB1 compared with the control (53.54% ± 8.96%, p < 0.01). Treatment with BBR
alone decreased the protein expression of SREB1 compared with the control (43.43% ± 16.4%, p < 0.05).
The OLZ + BBR co-treatment group showed observably lower SREB1 protein expression compared
with OLZ alone (57.71% ± 9.42%, p < 0.01) (Figure 3B,C).
We also measured the gene expression levels of Srebp2, Ldlr, and Hmgr, which were involved
in cholesterolopoiesis. The treatment with OLZ alone induced a significant elevation of Srebp2 and
Hmgr mRNA expression compared with the control group (79.37% ± 7.67%, 112.82% ± 8.07%, both
p < 0.01). However, treatment with OLZ alone tended to increase mRNA expression of Ldlr compared
with the control (p = 0.06). Treatment with BBR alone group reduced Ldlr and Hmgr markedly
compared with the control group (72.87% ± 11.36%, 59.06% ± 8.38%, both p < 0.05). Nonetheless,
when treated with BBR alone, there was no significant augmentation in mRNA expression level of
Srebp2 compared with the control (Figure 3A). Additionally, SREBP2 and LDLR protein expression
levels were consistent with that of their gene expression. Compared with the control, treatment with
OLZ alone significantly augmented the protein expression level of SREBP2 (94.27% ± 9.62%, p < 0.001)
and LDLR (31.03% ± 0.94%, p < 0.05). On the other hand, treatment with BBR alone decreased
the protein expression level of SREBP2 and LDLR compared with the controls (35.2% ± 10.49%,
28.47% ± 9.03%, both p < 0.05). OLZ + BBR co-treatment of 3T3-L1 cells distinctly decreased the
protein expression level of SREBP2 and LDLR compared with the group treated with OLZ alone
(73.05% ± 11.82%, p < 0.001, 59.46% ± 9.91%, p < 0.01) (Figure 3B,D,E).
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receptor-γ (PP Rγ) relative to P during 3T3-L1 cells treated ith LZ, BBR, or both for 72 h;
( ) the protein expression levels of S EBP-1, S EBP-2, and L L relative to - ctin of 3T3-L1 cells
treate it , , or bot for 72 a t eir q a tificatio , res ectively ( – ). reat e t it
as c tr l. al es given are the mean ± ( 3). * p 0.05, ** p 0.01 s. c tr l, p 0.05,
# p < 0.01 and ## p < .001 vs. treated with OLZ alone.
2.4. Effects of Treatment with OLZ, BBR, or Both on Expression of AMPKα-Related Adipogenesis in
ll
with OLZ alone compared with the control (22.51% ± 8%, p < 0.05) (Figure 4A,B). In compariso
with the control, treatment with BBR alone had an obviously levated pr tein expression of pAMPKα
(20.7% ± 2.1%, p < 0.05). OLZ + BBR co-treatment of 3T3-L1 cells enhanced the protein expression of
pAMPKα, but it wa not significant (p = 0.08). Treatment with OLZ alone had a significant effect on the
prot in expression level of AMPKα compared with the contr l (43% ± 3.95%, p < 0.01). OLZ + BBR
co-treatment group also decreased the prot in expression level of AMPKα by 24.07% ± 1.47% compared
with the treatment with OLZ al ne (p < 0.05). No significant differences were observed in the protein
expression level of AMPKα in treatment with BBR alon c mpared with the control (Figure 4A–C).
Treatment ith OLZ alone clearly decreased the ratio of pAMPKα:AMPKα compar d with the control
group (45.81% ± 3.22%, p < 0.05) (Figure 4D) whereas treatment with BBR alone increased the ratio
of pAMPKα:AMPKα by 36.11% ± 6.35% compared with the control (p < 0.05). The OLZ + BBR
-tre tment group increased the ratio of pAMPKα:AMPKα significantly compa d with OLZ- nly
group (94.09% ± 17.81%, p < 0.01) (Figure 4D).
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3. Discussion
In the present study, we investigated the inhibitory effect and underlying mechanisms of BBR on
OLZ-induced adipogenesis. OLZ + BBR co-treatment clearly inhibited adipogenesis and reversed the
enhancement of gene and protein expression levels of the SREBP pathway compared with treatment
with OLZ alone. In addition, the OLZ + BBR co-treatment had a significant rebound effect on the
phosphorylation level of AMPKα compared with the OLZ-only group. In summary, OLZ + BBR
co-treatment could reduce adipogenesis by modulating the SREBPs-AMPKα pathway.
Our data demonstrated that 10 µM OLZ could significantly augment the adipogenesis. A 10 µM
dose of OLZ increased mRNA expression levels of Srebp-related genes and improved the protein
expression levels of SREBP1, SREBP2, and LDLR. These results showed that OLZ upregulation of the
SREBP pathway was in relation to adipogenesis, which was consistent with the reports on several
cell lines and primary rat hepatocytes [11,12,31]. However, the ascending trend of mRNA expression
of Srebp2 was not significant, so it might be associated with emerging feedback adjustments in lipid
metabolism [32–34]. Simultaneously, we found that OLZ restrained the phosphorylation level of
pAMPKα in 3T3-L1 cells. AMPKα, a well-known metabolic regulator of energy metabolism, always
plays an important role at the cellular, as well as the whole body, level. There is some evidence that
AMPKα phosphorylation is facilitated in the hypothalamus and reduced in hepatocytes by OLZ,
implying that central and peripheral AMPKα activities could be dissimilarly regulated by the identical
stimulus [10,35–37]. Additionally, several studies have reported that AMPKα reduced lipid synthesis
by restraining SREBP activity and led to fatty acid oxidation in the liver to control hepatic energy
metabolism [18–20,38]. Like the effects of OLZ on hepatic AMPKα, our results suggested that AMPKα
activity was inhibited and that the SREBP pathway was upregulated in adipocytes upon exposure to
OLZ. Hence, our results showed that OLZ inhibited the phosphorylation of AMPKα to increase the
SREBP-regulated adipogenesis in 3T3-L1 cells.
Recently, it was reported that BBR could inhibit adipogenesis induced by clozapine and
risperidone through the SREBP-1-related pathway in 3T3-L1 cells [28]. BBR can also prevent weight
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gain induced by OLZ via the UCP-1-related pathway in rats [39]. In addition, pharmaceutical
compositions containing BBR could also be used to treat or prevent weight gain and obesity associated
with anti-psychotic drugs [40]. These reports indicate the effectiveness of BBR as an add-on treatment
in subjects starting treatment with OLZ for controlling SGA-related metabolic disorders. Our data
suggests that BBR had inhibitory effects on lipid metabolism by reducing the mRNA expression as
well as directly decreasing the protein expression of SREBP1, SREBP2, and LDLR. The inhibitory
effect involved in the SREBP-1 pathway was consistent with a previously reported impact of BBR
on adipogenesis induced by the clozapine and risperidone in 3T3-L1 cells [28]. However, the
underlying mechanisms of the inhibitory effect of BBR on cholesterolopoiesis were not entirely clear,
and further investigation is needed. In this study, BBR alone was able to downregulate the expression
of SREBP2 in relation to cholesterolopoiesis. Recently, it was determined that BBR also exerted
inhibitory actions on adipogenesis by improving the activation of AMPKα and promoting adiponectin
multimerization in 3T3-L1 cells [41]. In this study, BBR alone inhibited AMPKα–SREBP-related
adipogenesis in 3T3-L1 adipocytes. It has recently been reported that betahistine and OLZ co-treatment
ameliorated OLZ-induced weight gain and dyslipidemia through the modulation of histaminergic,
AMPKα–SREBP1, and PPARγ-dependent pathways [42]. Our data provides preliminary evidence that
BBR + OLZ co-treatment can prevent adipogenesis induced by OLZ.
It is noteworthy that there are several limitations in this study. Although this study showed that
BBR reduced the differentiation of adipocytes, cell division or the apoptosis of adipocytes were not
examined. Therefore, we could not completely exclude the possible effects of BBR on cell division or
the apoptosis of adipocytes, which could be an important issue for future studies. Another limitation
is that the current study has been conducted only in a cell culture; further study is necessary to
investigate whether BBR has the same inhibitory effect on dyslipidemia induced by OLZ in an animal
model for schizophrenia, which may provide crucial information for potential clinical trials to control
dyslipidemia caused by OLZ and other SGAs in patients with schizophrenia.
4. Materials and Methods
4.1. Materials
3T3-L1 cells were purchased from the Institute of Basic Medical Sciences, Chinese Academy of
Medical Sciences Cell Resource Center (Beijing, China). Berberine was purchased from the National
Institutes for Food and Drug Control (Beijing, China). An RNA Simple Total RNA Kit was purchased
from Tiangen Biotech Co., Ltd. (Beijing, China), a Transcriptor First Strand DNA Synthesis Kit
was obtained from Roche Diagnostics GmbH. (Basel, Switzerland). A SYBR Select Master Mix was
purchased from Thermo Fisher Scientific, Inc. (Foster City, CA, USA), and a Protein Assay Kit was
purchased from Transgen Biotech Co., Ltd. (Beijing, China). Commercially available TG and TC
assay kits were purchased from Nanjing Jiancheng Bioengineering Institute (Nanjing, China). Primary
antibodies against SREBP1, SREBP2, and LDLR were obtained from Abcam, Inc. (Cambridge, MA,
USA), and β-Actin was obtained from Beijing Bioss Biotech Co., Ltd. (Beijing, China). Primary
antibodies against AMPKα, pAMPKα, and anti-rabbit IgG-conjugated horseradish peroxidase (HRP)
antibody were purchased from Cell Signaling Technology, Inc. (Beverly, MA, USA).
4.2. Culturing 3T3-L1 Fibroblasts and Differentiation into Adipocytes
3T3-L1 fibroblasts were grown and maintained in DMEM containing 10% fetal bovine serum (FBS)
(Figure 5A). To guarantee better observation clarity, differentiation began 2 days after the cells reached
moderate confluence (denoted as Day 0) (Figure 5B), and cells were fed with prior-differentiation
medium (DM) (DMEM, 10% FBS, 2 µg/mL of insulin, 100 ng/mL of dexamethasone, 500 µM
3-isobutyl-1-methylxanthine (IBMX), 100 ng/mL of D-Biotin). On Day 3, cells were incubated with
post-differentiation medium (DMEM, 10% FBS, 2 µg/mL Insulin) for a further 3 days. Thereafter,
adipocytes were fed with complete medium (DMEM, 10% FBS) every 3 days. A small amount of
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old medium was be removed gently. Cells were ready for use on Day 12 (Figure 5C). Lipid droplets
formed by TG accumulation were clearly presented in adipocytes.
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Figure 5. The condition of 3T3-L1 fibroblasts differentiation into adipocytes. (A) The differentiation
protocol of 3T3-L1 into adipocytes; (B) the microscopic image of 3T3-L1 fibroblasts; (C) the microscopic
image of 3T3-L1 adipocytes. DM: Abbreviation of differentiation medium. Scale bars, 100 µm. Inset
images were magnified to highlight the cell morphology.
4.3. Oil-Red-O Staining
Differentiated 3T3-L1 cells were washed twice with PBS on Day 12. Monolayer cells were fixed
on culture dishes with 4% paraformaldehyde at 37 ◦C for 40 min. After being washed with chilled
PBS for three times, cells were incubated with ORO solution (0.3% ORO, 60% isopropanol, and 40%
water) for 2 h at 37 ◦C. They were then rinsed thoroughly with water to eliminate unbound dyestuff
on the surface of the monolayer at least 4 times. The number of staining lipid droplets of adipocyte
was observed and imaged under an inverted microscope.
4.4. TG and TC Assay
Differentiated 3T3-L1 cells were washed with cold PBS 3 times on Day 12 and then scraped,
followed by centrifugation at 1000× g for 10 min. After the supernatant was discarded, the remaining
pellets were combined with 300 µL of ice-cold PBS (pH 7.4). Cells were cleaved by sonication (power,
300 W; per 3–5 s; pause 25 s; repeat 3 to 5 times). The supernatant was collected after centrifugation at
12,000× g for 15 min, and the concentration was determined via Protein Assay Kit. The concentrations
of TG and TC in supernatant were analyzed by enzymology using the kits. All experimental assays
were performed in accordance with the manufacturer’s instructions.
4.5. a titative eal- i e PCR (qRT-PCR)
otal RNA isolation was obtained according to the protocol recommended by the manufacturers.
Total RNA was dissolved in pure water a d sample integrity was checked by 1.5% agarose gel
electrophoresis and quantified at 260/280 nm. cDNA was synthesized using Transcriptor First Strand
DNA Synthesis Kit. For qRT-PCR, reactions were performed on the MyCyclerTM system (Bio-Rad,
Hercules, CA, USA) using the SYBGR Select Master Mix (Applied Biosystems, Foster City, CA, USA).
The primer sequences are shown in Table 1. The relative mRNA levels of these genes were calculated
by the 2−∆∆Ct method and normalized with control-treated groups.
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3T3-L1 cells were washed with 4 ◦C PBS twice. A mixture of RIPA Lysates and 1% 0.5 mM PMSF
was added to the monolayer cells on the ice. After the cells were gently shaken and beaten, the lysate
was collected and immediately centrifuged at 12,000× g at 4 ◦C for 10 min. The supernatant was saved
as a protein extraction at −86 ◦C.
Protein concentrations were quantified utilizing a Protein Assay Kit. The homogenized samples
(30 µg) were separated by SDS-PAGE (sodium dodecyl sulfate-polyacrylamide gel electrophoresis)
using the BioRad Electrophoretic System (80 V for 0.5 h followed by 120 V for 2 h) and then transferred
to a PVDF membrane at 4 ◦C. The PVDF membrane was blocked with 5% non-fat milk in TBST
(0.1% Tween 20 in Tris-buffered saline) at room temperature for 1 h. The membrane was washed
with TBST for three times (per 10 min), followed by incubation with a primary antibody at 4 ◦C
overnight. The membrane was rinsed three times with TBST, then incubated with horseradish
peroxidase-conjugated (HRP) secondary antibody at room temperature for 1 h. The protein expression
of SREBP1, SREBP2, LDLR, pAMPKα, AMPKα, and the loading control β-Actin was detected by
the ECL kit standard protocol. The band intensities were analyzed and quantified using Quantity One
software (Bio-Rad).
4.7. Statistics
Data analysis was performed by the SPSS 19.0 procedure (Chicago, IL, USA). Results were
presented as the mean ± SEM (x ± s). Statistical analysis used by a one-way analysis of variance
(ANOVA) followed by a Tukey’s post hoc test for multiple comparisons. p < 0.05 was considered
statistically significant.
5. Conclusions
Our data demonstrated that OLZ could induce dyslipidemia side effects by the regulation of
AMPKα–SREBP pathway. In addition, co-treatment with BBR could partially reduce OLZ-induced
adipogenesis through the AMPKα–SREBP-related pathway in 3T3-L1 adipocytes. Nevertheless, we
measured the biochemical criteria (TG and TC) and gene expression through qRT-PCR array analysis
and Western blot in vitro, and it is necessary to further investigate in vivo. The results not only
supply one possible mechanism of the decrease in OLZ-induced adipogenesis by BBR but also provide
a combination therapy project for schizophrenia-induced dyslipidemia.
Supplementary Materials: Supplementary materials can be found at www.mdpi.com/1422-0067/17/11/1865/s1.
Int. J. Mol. Sci. 2016, 17, 1865 10 of 12
Acknowledgments: This study was funded by the Key Program of Chongqing Science and Technology Research
Project Foundation of China (No. Cstc2013jcsf10002) and Fundamental Research Funds for the Central Universities
(No. XDJK2016D030). Chao Deng is supported by an NHMRC (National Health and Medical Research Council)
project grant (APP1044624).
Author Contributions: Chang-Hua Hu and Yanjie Li searched the literature and designed the experiment.
Yanjie Li performed the 3T3-L1 adipocyte model and ORO staining. Yanjie Li, Xiaomin Zhao, and Xiyu Feng
performed TG and TC assays and qRT-PCR. Yanjie Li and Xuemei Liu performed Western blot analysis. Yanjie Li
and Chao Deng conducted statistical analysis and interpreted the data. Yanjie Li prepared the initial draft of
the manuscript. All authors discussed the results and commented on the manuscript.
Conflicts of Interest: The authors declare no conflict of interest. The funding sources had no role in design of
the study, analysis of data, or the writing of the manuscript.
Abbreviations
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